| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/11/2010 | EP2216028A2 Immunostimulation by chemically modified RNA |
| 08/11/2010 | EP2216027A2 Chemically modified RNA for immunpstimulation |
| 08/11/2010 | EP2216026A1 Ophthalmic compositions and uses for treating ophthalmic conditions |
| 08/11/2010 | EP2216025A2 Use of acylaminoalkenylene-amide derivatives in irritable bowel syndrome and functional dyspepsia |
| 08/11/2010 | EP2216024A2 Use of Ranolazine for the treatment of cardiovascular diseases |
| 08/11/2010 | EP2216023A1 Condensed pyridine derivative and use thereof |
| 08/11/2010 | EP2216022A1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 08/11/2010 | EP2216021A1 Pharmaceutical composition for treating overactive bladder |
| 08/11/2010 | EP2216020A1 Moisture-activated granulation process |
| 08/11/2010 | EP2216019A2 Ophthalmic uses of S1P receptor modulators |
| 08/11/2010 | EP2216018A1 Transdermal delivery systems |
| 08/11/2010 | EP2216017A1 Mucosal bioadhesive slow release carrier for delivering active principles |
| 08/11/2010 | EP2216016A1 Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| 08/11/2010 | EP2215915A1 Citrulline-containing drink |
| 08/11/2010 | EP2215913A1 Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed |
| 08/11/2010 | EP2215147A2 Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery |
| 08/11/2010 | EP2215114A1 Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides |
| 08/11/2010 | EP2215095A1 Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c |
| 08/11/2010 | EP2215094A1 N-containing heterocyclic compounds |
| 08/11/2010 | EP2215093A1 Novel piperazino-dihydrothienopyrimidine derivatives |
| 08/11/2010 | EP2215092A1 Substituted piperidino-dihydrothienopyrimidines |
| 08/11/2010 | EP2215091A2 Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| 08/11/2010 | EP2215090A1 Purine derivatives useful as pi3 kinase inhibitors |
| 08/11/2010 | EP2215089A1 [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| 08/11/2010 | EP2215087A2 Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine |
| 08/11/2010 | EP2215085A2 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| 08/11/2010 | EP2215084A2 Therapeutic substituted lactams |
| 08/11/2010 | EP2215082A1 Phthalazine and pyrido ý3,4-d¨pyridaz ine compounds as h1 receptor antagonists |
| 08/11/2010 | EP2215080A1 Diazepane compounds which modulate the cb2 receptor |
| 08/11/2010 | EP2215079A1 Inhibitors of c-fms kinase |
| 08/11/2010 | EP2215078A1 Azetidinyl g-protein coupled receptor agonists |
| 08/11/2010 | EP2215077A1 Azetidinyl g-protein coupled receptor agonists |
| 08/11/2010 | EP2215074A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| 08/11/2010 | EP2215073A1 Modulation of sleep with nr2b receptor antagonists |
| 08/11/2010 | EP2215072A2 Polymorphic form of rotigotine |
| 08/11/2010 | EP2215068A1 Antidiabetic tricyclic compounds |
| 08/11/2010 | EP2215067A1 Amino-heteroaryl-containing prokineticin 1 receptor antagonists |
| 08/11/2010 | EP2215066A1 Amide derivatives as sirtuin modulators |
| 08/11/2010 | EP2215064A1 Compounds for inhibiting ksp kinesin activity |
| 08/11/2010 | EP2215061A2 Trpv1 antagonists |
| 08/11/2010 | EP2215059A2 Novel heteroaryl-substituted acetone derivative, suitable for inhibiting phospholipase a2 |
| 08/11/2010 | EP2215058A1 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
| 08/11/2010 | EP2215055A1 New non-peptide derivatives as bradykinin b1 antagonists |
| 08/11/2010 | EP2215052A1 Desferrioxamine conjugates, derivatives and analogues |
| 08/11/2010 | EP2215044A1 Biphenyl carboxylic acids and derivatives thereof |
| 08/11/2010 | EP2215043A1 Carbon linked modulators of y-secretase |
| 08/11/2010 | EP2214715A1 Method of delivering an anti-cancer agent to a cell |
| 08/11/2010 | EP2214714A1 A new class of therapeutics that enhance small molecule diffusion |
| 08/11/2010 | EP2214713A1 Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia |
| 08/11/2010 | EP2214712A1 Compositions and methods for treating asthma and lung disorders |
| 08/11/2010 | EP2214684A1 Vaginal lubricant comprising hyaluronic acid |
| 08/11/2010 | EP2214681A1 Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof |
| 08/11/2010 | EP2214680A1 Pharmaceutical formulation of clavulanic acid |
| 08/11/2010 | EP2214678A2 Compositions for the treatment of gastrointestinal inflammation |
| 08/11/2010 | EP2214676A1 Substituted diazepan orexin receptor antagonists |
| 08/11/2010 | EP2214675A1 Process for making thienopyrimidine compounds |
| 08/11/2010 | EP2214674A1 Inhibitors of anti-apoptotic proteins |
| 08/11/2010 | EP2214673A1 Novel phenyl-substituted piperazino-dihydrothienopyrimidines |
| 08/11/2010 | EP2214672A2 Combination analgesic employing opioid and neutral antagonist |
| 08/11/2010 | EP2214671A1 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs |
| 08/11/2010 | EP2214670A2 Compounds for treating abnormal cellular proliferation |
| 08/11/2010 | EP2214669A1 Cytokine inhibitors |
| 08/11/2010 | EP2214667A2 Small molecule inhibitors of parp activity |
| 08/11/2010 | EP2214666A1 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| 08/11/2010 | EP2214665A1 Compounds for preventing or treating a viral infection |
| 08/11/2010 | EP2214664A2 Brca1-based breast or ovarian cancer prevention agents and methods of use |
| 08/11/2010 | EP2214663A1 Sphingosine- 1- phosphate (s1p) receptor compounds |
| 08/11/2010 | EP2214662A1 Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| 08/11/2010 | EP2214660A2 Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions |
| 08/11/2010 | EP2214659A1 Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders |
| 08/11/2010 | EP2214658A1 Osmolyte-containing preparation for use in case of dry mucous membranes |
| 08/11/2010 | EP2214657A1 Compounds for treating demyelination conditions |
| 08/11/2010 | EP2214656A1 Compositions and methods for enhancing immune response |
| 08/11/2010 | EP2214655A1 Compositions containing resveratrol and pectin |
| 08/11/2010 | EP2214653A2 Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
| 08/11/2010 | EP2214651A1 Nifedipine-containing press coated tablet and method of preparing the same |
| 08/11/2010 | EP2214649A1 Compositions for treating parkinson's disease |
| 08/11/2010 | EP2214647A2 Delivery of active agents |
| 08/11/2010 | EP2214645A2 Liposomal vancomycin formulations |
| 08/11/2010 | EP2214644A2 Water-immiscible materials as vehicles for drug delivery |
| 08/11/2010 | EP2214643A1 Transdermal delivery system for hormones and steroids |
| 08/11/2010 | EP2214642A1 Topical composition |
| 08/11/2010 | EP2214641A1 A scalable matrix for the in vivo cultivation of bone and cartilage |
| 08/11/2010 | EP2214640A1 Intranasal compositions |
| 08/11/2010 | EP2214639A2 Anesthetic composition, formulation and method of use |
| 08/11/2010 | EP2214637A1 Stabilized pediatric suspension of carisbamate |
| 08/11/2010 | EP2214628A1 Orodispersible composition comprising polyunsaturated fatty acids without bad odour or taste |
| 08/11/2010 | EP2214518A1 Metabolic enhancement therapy |
| 08/11/2010 | EP2214491A1 Quinolone analogs and methods related thereto |
| 08/11/2010 | EP2214488A1 Compositions and methods for treating parkinson's disease and related disorders |
| 08/11/2010 | EP2214487A1 Novel seh inhibitors and their use |
| 08/11/2010 | EP2214485A1 Methods for treatment of cancer |
| 08/11/2010 | EP2214484A1 Process for the preparation of macrolide antibacterial agents |
| 08/11/2010 | EP2214482A1 Prostaglandin analog compositions and methods to treat epithelial-related conditions |
| 08/11/2010 | EP2214481A1 Method for increasing performance of offspring |
| 08/11/2010 | EP2214480A1 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| 08/11/2010 | EP2099763B1 2-aminoquinolines as 5-ht(5a) receptor antagonists |
| 08/11/2010 | EP2097373B1 Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl ) |
| 08/11/2010 | EP2049529B1 Substituted diazepan orexin receptor antagonists |
| 08/11/2010 | EP1984522B1 Methods of increasing lymphatic function |